ALEXIS Biochemicals: Lavendustin A

ALX-350-007

Revised 07-Apr-08

Lavendustin A
SYNONYMS	5-Amino-[(N-2,5-dihydroxybenzyl)-N'-2-hydroxybenzyl]salicylic acid RG14355
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Natural Products - Protein Kinase Inhibitors

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-350-007-M001		1 mg	75.00 USD
ALX-350-007-M005		5 mg	295.00 USD

Product Specification

FORMULA:	C₂₁H₁₉NO₆
MW:	381.4
CAS NUMBER:	125697-92-9
SOURCE/HOST:	Synthetic.
PURITY:	≥97% (TLC)
APPEARANCE:	Off-white to brown solid.
SOLUBILITY:	Soluble in DMSO, methanol or dilute aqueous base.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light and moisture. Hygroscopic.

Product Description

Cell permeable tyrosine kinase inhibitor with little effect on cAMP-dependent protein kinase (PKA) or protein kinase C (PKC). Inhibits autophosphorylation of EGFRs. Also inhibits NMDA-stimulated cGMP production.

Product Specific Literature References

Cellular oncogenes and retroviruses: J.M. Bishop; Annu. Rev. Biochem. 52, 301 (1983) Abstract
Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus: T. Onoda, et al.; J. Nat. Prod. 52, 1252 (1989) Abstract
Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by Lavendustin-A and its analogue: C.-Y.J. Hsu, et al.; J. Biol. Chem. 266, 21105 (1991) Abstract
Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors: T.J. O'Dell, et al.; Nature 353, 558 (1991) Abstract
Blockade of nitric oxide synthesis by tyrosine kinase inhibitors in neurones: J. Rodriguez, et al.; Neuropharmacology 33, 1267 (1994) Abstract
Solid Phase Synthesis of Lavendustin A and Analogs: J. Green; J. Org. Chem. 60, 4287 (1995)
Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A: D.E. Hu and T.-P.D. Fan; Br. J. Pharmacol. 114, 262 (1995) Abstract
Inhibition of atrial wall stretch-induced cardiac hormone secretion by lavendustin A, a potent tyrosine kinase inhibitor: P. Taskinen, et al.; Endocrinology 140, 4198 (1999) Abstract
Influence of the tyrosine kinase inhibitors STI571 (Glivec(R)), lavendustin A and genistein on human mast cell line (HMC-1(560)) activation: K. Lober, et al.; J. Cell Biochem. 103, 1076 (2007) Abstract